group

CIRM Alpha Stem Cell Clinic at UC Davis Health

CIRM Alpha Stem Cell The CIRM-funded Alpha Stem Cell Clinics are a network of top California medical centers. The Network specializes in delivering stem cell clinical trials to patients. The key to the Network’s success is the ability to accelerate the delivery treatments to patients through partnerships with patients, medical providers and clinical trial sponsors. These partnerships enable:

  • Patient-centered clinical trials with the highest standards of care and research
  • Strategic collaboration with academic and industry teams developing innovative stem cell therapies
  • Leveraging of resources to promote efficiency, acceleration and increased chances of success

 

Visit the following web page to learn of current stem cell clinical trials at UC Davis Alpha Stem Cell Clinic:  

https://studypages.com/ucdavis/studies/?center=stem-cell-clinic

Patients interested in participating in Stem Cell Clinical Trials please phone 916-703-9302

CURRENTLY ENROLLING – ACTIVE TRIALS

  • Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia (NCT02838316)
    Disease: Tongue Dysphagia
    Sponsor: UC Davis Cook Myosite
    PI: Peter Belafsky, M.D.
  • Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy (NCT01736059)
    Disease: Retinopathy
    Sponsor: UC Davis
    PI: Susanna Park, M.D.
  • A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Delivered Cells in Subjects with Duchenne Muscular Dystrophy (HOPE-2) (NCT03406780)
    Disease: DMD
    Sponsor: Capricor
    PI: Craig McDonald, M.D.
  • A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (NCT02578641)
    Disease: Nasopharyngeal Carcinoma
    Sponsor: TESSA
    PI: Mehrdad Abedi, M.D.
  • Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML (NCT03301597)
    Disease: Neutropenia
    Sponsor: CIRM Nohla
    PI: Mehrdad Abedi, M.D.
  • Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant (NCT02797470)
    Disease: HIV-NHL
    Sponsor: CIRM
    PI: Mehrdad Abedi, M.D.

CLINICAL TRIALS IN PROCESS: PLEASE CHECK BACK

  • Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants (NCT03363945)
    Disease: Kidney Transplant
    Sponsor: Medeor Therapeutics
    PI: Junichiro Sageshima, M.D.
  • Study of ET190L1-ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma (NCT03379493)
    Disease: Non-Hodgkins Lymphoma
    Sponsor: Eureka
    PI: Mehrdad Abedi, MD
  • A Phase 3 Study Comparing the Utility of Human Acellular Vessels to Arteriovenous Fistula in Subjects with End Stage Renal Disease (NCT03183245)
    Disease: Renal Disease
    Sponsor: CIRM Humacyte
    PI: Junichiro Sageshima, M.D.
  • Multicenter Expanded Access Protocol of ATA129 for Subjects with Epstein-Barr Virus-Associated Viremia or Malignancies for Whom there are No Appropriate Alternative Therapies ATA129-EBV-201 (NCT02822495 )
    Disease: EBV-PTLD
    Sponsor: Atara Biotherapeutics
    PI: Mehrdad Abedi, M.D.
  • ATA129 for Solid Organ Transplant Subjects With EBV-PTLD After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) ATA129-EBV-302 (NCT03394365)
    Disease: EBV-PTLD
    Sponsor: Atara Biotherapeutics
    PI: Mehrdad Abedi, M.D.
  • Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (NCT03451916)
    Disease: Muscle Injury following arthroplasty for HF
    Sponsor: Pluristem
    PI: Mark Lee, M.D.
  • A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies (NCT03420183)
    Disease: B-Cell Leukemia
    Sponsor: CIRM UCSD
    PI: Joe Tuscano, M.D.
  • A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers KITE 718-301 (NCT03139370)
    Disease: Advanced Cancer
    Sponsor: Kite
    PI: Mehrdad Abedi, M.D.
  • Phase II Trial of Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma (NCT03400917)
    Disease: Glioblastoma
    Sponsor: AIVITA Biomedical
    PI: Robert O’Donnell, M.D., Ph.D.
  • An Open Label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy Of Singel or Multiple Applications of Stratagraft® Skin Tissue as an Alternative to Autografting Full-Thickness Complex Skin Defects STRATA2014 (NCT03005054)
    Disease: Burns
    Sponsor: Mallinckrodt Pharmaceuticals
    PI: Tina Palmieri, M.D.
  • A Phase III Open-label, Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of StrataGraft Skin Tissue in Promoting Autologous Skin Tissue Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements and for Which Excision and Autografts Are Clinically Indicated STRATA2016 (NCT03005106)
    Disease: Burns
    Sponsor: Mallinckrodt Pharmaceuticals
    PI: Tina Palmieri, M.D.
  • A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI) (NCT02551679)
    Disease: Critical Limb Ischemia
    Sponsor: Hemostemix
    PI: Matthew Mell, M.D.